Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): A systematic review and economic analysis

Health Technology Assessment

Volumn 15, Issue 42, 2011, Pages

  Fleeman, N ^a   Bagust, A ^a   Boland, A ^a   Dickson, R ^a   Dundar, Y ^a   Moonan, M ^a   Oyee, J ^a   Blundell, M ^a   Davis, H ^b   Armstrong, A ^c   Thorp, N ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b North West Medicines Information Centre ^*  (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; LAPATINIB; LETROZOLE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; NITRILE; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

BIBLIOGRAPHIC DATABASE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HUMAN; MONOTHERAPY; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; TIME TO PROGRESSION; BREAST TUMOR; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; ECONOMICS; FEMALE; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NITRILES; QUINAZOLINES; RECEPTOR, ERBB-2; TRIAZOLES;

EID: 84856333750     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta15420     Document Type: Review

References (114)

1. Germano S, O'Driscoll L. Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. Curr Cancer Drug Targets 2009;9:398-418.
2. Cancer Research UK. Breast cancer-risk factors. 2010. URL: http://info.cancerresearchuk.org/cancerstats/types/breast/riskfactors/ (accessed: 6 September 2010).
3. Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007;11(40).
4. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-6.
5. Hannah L, Crosby T, MacBeth F, editors. Practical clinical oncology. 1st edn. Cambridge: Cambridge University Press; 2008.
6. Endogenous Hormones Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
7. Cassidy J, Bissett D, Spence R, Payne M, editors. Oxford handbook of oncology. 2nd edn. Oxford: Oxford: Oxford University Press; 2006.
8. American Joint Committee on Cancer. AJCC cancer staging manual. 7th edn. Chicago, IL: Springer; 2009.
9. International Union Against Cancer. TNM classification of malignant tumours. 7th edn. New York, NY: Wiley-Liss; 2009.
10. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-18.
11. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
12. Cancer Research UK. Predicted improvements in breast cancer survival cancer research UK. 2010. URL: www.cancerhelp.org.uk/about-cancer/cancer-questions/predictedimprovements-in-breast-cancer-survival (accessed 6 September 2010).
13. Andreopoulou E, Hortobagyi GN. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol 2008;26:3660-2.
14. Cold S, Jensen NV, Brincker H, Rose C. The influence of chemotherapy on survival after recurrence in breast-cancer-a population-based study of patients treated in the 1950s, 1960s and 1970s. Eur J Cancer 1993;29:1146-52.
15. National Institute for Health and Clinical Excellence (NICE). Guidance on the use of trastuzumab for the treatment of advanced breast cancer. NICE technology appraisal guidance. No.34. 2002. URL: www.nice.org.uk/nicemedia/pdf/TA107guidance.pdf (accessed 26 January 2010).
16. Cancer Research UK. Breast cancer-UK incidence statistics. 2010. URL: http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/ (accessed 18 August 2011).
17. Quinn M, Cooper N, Rowan S. Cancer atlas of the United Kingdom and Ireland 1991-2000. 2005. URL: www.statistics.gov.uk/downloads/theme_health/caUKI91_00/Preliminary_pages.pdf (accessed 14 July 2010).
18. Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol 2006;17:5-19.
19. GlaxoSmithKline. Manufacturer submission to the National Institute for Health and Clinical Excellence by GlaxoSmithKline UK. Multiple technology appraisal of lapatinib (Tyverb®) for the treatment of HR+ HER2+ metastatic breast cancer. Date 7 June 2010.
20. Roche. Trastuzumab in combination with aromatase inhibitors for the 1st line treatment of metastatic hormone receptor positive breast cancer which over-expressed HER2. Roche submission to the National Institute for Health and Clinical Excellence. Date 7 June 2010.
21. Dybdal N, Leiberman G, Anderson S, McCune B, Bajamonde A, Cohen R, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005;93:3-11.
22. Turner J, Kelly B, Swanson C, Allison R, Wetzig N. Psychosocial impact of newly diagnosed advanced breast cancer. Psychooncology 2005;14:396-407.
23. National Institute for Health and Clinical Excellence (NICE). Advanced breast cancer: diagnosis and treatment. NICE clinical guideline. No. 81. 2009. URL: www.nice.org.uk/Guidance/CG81 (accessed 26 January 2010).
24. Quinlan E, Thomas-Maclean R, Hack T, Kwan W, Miedema B, Tatemichi S, et al. The impact of breast cancer among Canadian women: disability and productivity. Work 2009;34:285-96.
25. Yoo GJ, Levine EG, Aviv C, Ewing C, Au A. Older women, breast cancer, and social support. Support Care Cancer 2010;18:1521-30.
26. Montazeri A, Vahdaninia M, Harirchi I, Ebrahimi M, Khaleghi F, Jarvandi S. Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow-up study. BMC Cancer 2008;8:330.
27. Kedrin D, Wyckoff J, Boimel PJ, Coniglio SJ, Hynes NE, Arteaga CL, et al. ERBB1 and ERBB2 have distinct functions in tumor cell invasion andi. Clin Cancer Res 2009;15:3733-9.
28. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 59, March 2010. London: BMA and RPS; 2010.
29. European Medicines Agency (EMA). Committee for medicinal products for human use post-authorisation summary of positive opinion for tyverb. 2010. URL: www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000795/WC500074419.pdf (accessed 24 November 2010).
30. European Medicines Agency (EMA). Committee for medicinal products for human use summary of positive opinion for tyverb. 2008. URL: www.ema.europa.eu/pdfs/human/opinion/Tyverb_38267507en.pdf (accessed 26 January 2010).
31. Pharmaceutical Field. Further indication for tyverb approved. 2010. URL: www.pharmafield.co.uk/news/2010/06/further-indication-for-tyverb-approved (accessed 14 July 2010).
32. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009;100:684-92.
33. European Medicines Agency (EMA). Committee for medicinal products for human use postauthorisation summary of positive opinion for herceptin. 2009. URL: www.ema.europa.eu/pdfs/human/opinion/Herceptin_82246709en.pdf (accessed 26 January 2010).
34. National Institute for Health and Clinical Excellence (NICE). Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer. Technology appraisal No. TA112. 2006. URL: www.nice.org.uk/TA112 (accessed 26 January 2010).
35. Lavelle K, Todd C, Moran A, Howell A, Bundred N, Campbell M. Non-standard management of breast cancer increases with age in the UK: a population based cohort of women greater than or equal to 65 years. Br J Cancer 2007;96:1197-203.
36. Wyld L, Garg DK, Kumar ID, Brown H, Reed MWR. Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer 2004;90:1486-91.
37. Ladva S. Continued use of trastuzumab following disease progression in metastatic breast cancer. London: New Drugs Group; 2010.
38. Centre for Reviews and Dissemination (CRD). CRD's guidance for undertaking reviews in healthcare: systematic reviews. 3rd edn. York: CRD, University of York; 2008.
39. Egger M, Smith GD, Altman DG. Systematic reviews in health care-meta-analysis in context. London: BMJ books; 2001.
40. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24.
41. Langer B. Phase II/III randomized study of anastrozole with or without trastuzumab (herceptin) in postmenopausal women with hormone-receptor positive HER2-overexpressing metastatic breast cancer. Physician Data Query (PDQ). 2001. URL: www.mrw.interscience.wiley.com/cochrane/clcentral/articles/021/CN-00362021/frame.html (accessed 30 June 2010).
42. Piccart-Gebhart MJ, Coleman RE. Phase III randomized study of trastuzumab (herceptin) in women with HER2-positive primary breast cancer. Physician Data Query (PDQ). 2002. URL: www.mrw.interscience.wiley.com/cochrane/clcentral/articles/007/CN-00404007/frame.html (accessed 30 June 2010).
43. Stein S. Phase III randomized study of letrozole with or without GW572016 in postmenopausal women with stage IIIB or IV breast cancer. Physician Data Query (PDQ). 2004: URL: www.mrw.interscience.wiley.com/cochrane/clcentral/articles/289/CN-00548289/frame.html (accessed 30 June 2010).
44. Novartis. Study of the efficacy and safety of letrozole combined with trastuzumab in patients with metastatic breast Ccancer. Physician Data Query (PDQ). 2006. URL: www.mrw.interscience.wiley.com/cochrane/clcentral/articles/302/CN-00614302/frame.html (accessed 30 June 2010).
45. Morris P, Modi S. Trastuzumab-refractory HER2-positive metastatic breast cancer-use of tanespimycin, a novel Hsp90 inhibitor. Am J Pediatr Hematol Oncol 2008;7.
46. Maung K, O'Shaughnessy JA. Inhibition of ErbB1 and ErbB2 by lapatinib ditosylate, a dual kinase inhibitor: promising activity in pretreated advanced breast cancer. Clin Breast Cancer 2004;4:398-400.
47. Ranganathan A, Moore Z, O'Shaughnessy JA. Trastuzumab prolongs progression-free survival in patients with hormone-sensitive and HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2007;7:450-1.
48. Johnston S, Arteaga C. Lapatinib (tykerb) plus letrozole (femara) or letrozole alone for postmenopausal hormone receptor-positive metastatic breast cancer. P and T 2009;34:102.
49. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
50. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-37.
51. Schwarzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston SRD. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010;15:122-9.
52. Huober J, Fasching P, Paepke S, Kubista E, Barsoum M, Wallwiener D, et al. Letrozole in combination with trastuzumab is superior to letrozole monotherapy as first line treatment in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer (MBC)-results of the eLEcTRA Trial. Cancer Res 2009;69:4094.
53. Gomez HL, Doval DC, Chavez MA, Ang PC-S, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005.
54. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu C, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-43.
55. Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. 2007. URL: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf (accessed 22 July 2010).
56. Committee for Medicinal Products for Human Use. Guideline on the evaluation of anticancer medicinal products in man. 2005. URL: www.tga.gov.au/docs/pdf/euguide/ewp/020595enrev3.pdf (accessed 22 July 2010).
57. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009;27:2874-80.
58. Saad ED, Katz A. Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol 2009;20:460-4.
59. Sherif B, Sherrill B, Amonkar M, Wu Y, Maltzman J, O'Rourke L, et al. Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor-positive HER2+ metastatic breast cancer (MBC): a quality-of-life (QOL) analysis. J Clin Oncol 2009;27:abstr 1039.
60. Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Comm Stat Theor 1991;20:2609-31.
61. Mark SD, Robins JM. A method for the analysis of randomized trials with compliance information: an application to the multiple risk factor intervention trial. Control Clin Trials 1993;14:79-97.
62. Morden JP, Lambert PC, Latimer N, Abrams KR, Wailoo AJ. Assessing methods for dealing with treatment switching in randomised controlled trials. University of Leicester. 2010. URL: www.le.ac.uk/hs/kra1/2010_BS01.pdf (accessed 17 August 2010).
63. National Institute for Health and Clinical Excellence (NICE). Final appriasal determination: sunitinib for the treatment of gastrointestinal stromal tumours. 2009. URL: www.nice.org.uk/nicemedia/live/11817/43174/43174.pdf (accessed 17 August 2010).
64. National Institute for Health and Clinical Excellence (NICE). Final appraisal determination: everolimus for the second-line treatment of advanced renal cell carcinoma. 2010. URL: http://guidance.nice.org.uk/TA/WaveCRS1/48 (accessed 17 August 2010).
65. Robins J, Finkelstein D. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000;56:779-88.
66. Branson M, Whitehead J. Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med 2002;21:2449-63.
67. Walker A, White I, Babiker A. Parametric randomization-based methods for correcting for treatment changes in the assessment of the causal effect of treatment. Stat Med 2004;23:571-90.
68. Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000;18:3748-57.
69. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758-67.
70. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997;79:730-9.
71. Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32:404-12.
72. Parmar M, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34.
73. Bucher H, Guyatt G, Griffith L, Walter S. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91.
74. Sutton AJ, Higgins JPT. Recent developments in meta-analysis. Oxford: John Wiley & Sons, Ltd; 2008. pp. 625-50.
75. Puhan M, Bachmann L, Kleijnen J, ter Riet G, Kessels A. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network metaanalysis. BMC Med 2009;7:2.
76. Mouridsen HT. Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 2007;105:19-29.
77. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357-66.
78. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61.
79. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Cervek J, et al. Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. Results of a double-blind randomised phase III trial. Eur J Cancer 2000;36:S86-7.
80. Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Becquart D, Chaudri-Ross HA, et al. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist 2004;9:489-96.
81. Paridaens R, Dirix L, Beex L, Nooij M, Cufer T, Lohrisch C, et al. Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. Clin Breast Cancer 2000;1:S19-21.
82. Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39:2318-27.
83. Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP, Cameron DA. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009;9:39-44.
84. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403.
85. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-95.
86. Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-5.
87. Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008;26:4883-90.
88. Chernozemsky I, Kalinov K, Tzekov H, Racheva M, Hristova S, Tomova A, et al. Randomized phase III trial of exemestane or tamoxifen in first-line hormonal treatment of postmenopausal women with metastatic breast cancer. Breast Cancer Res Treat 2007;106:S119.
89. Mauriac L, Romieu G, Bines J. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res Treat 2009;117:69-75.
90. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399-411.
91. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess 2007;11(26).
92. Dranitsaris G, Leung P, Mather J, Oza A. Cost utility analysis of second line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs 2000;11:591-601.
93. Dranitsaris G, Verma S, Trudeau M. Cost utility analysis of first-line hormonal therapy in advanced breast cancer. Am J Clin Oncol 2003;26:289-96.
94. Marchetti M, Caruggi M, Colombo G. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature based model analysis of cost in the Italian national health service. Clin Ther 2004;26:1546-61.
95. Verma S, Rodchi A. Economic evaluation of antiaromatase agents in the second line treatment of metastatic breast cancer. Support Care Cancer 2003;11:728-34.
96. Hastings V, Amonkar M, Lykopoulos K, Diaz J, Johnston S. Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET+LAP) versus anastrozole plus trastuzumab (ANA + TZ) as first-line treatment for postmenopausal women with HER2+ and HR+ metastatic breast cancer (MBC) from the U.K. national health service (NHS) perspective. ASCO 2010, abstract no. 1035. Poster presented in Chicago, IL, USA, June 2010.
97. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence; 2008. URL: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed 26 January 2010).
98. Curtis L. Unit costs of health and social care 2008. Kent: Personal Social Services Research Unit, University of Kent; 2008. URL: www.pssru.ac.uk/uc/uc2008contents.htm (accessed 25 August 2010).
99. Department of Health. NHS reference costs 2008-2009. 2010. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591 (accessed 25 August 2010).
100. Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 2004;91:77-83.
101. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
102. Dobrez D, Cella D, Pickard S, Lai J-S, Nickolov A. Estimation of patient preference-based utility weights from the functional assessment of cancer therapy-general. Value Health 2007;10:266-72.
103. Delea TE et al. Patient preference-based utility weights from the Functional Assessment of Cancer Therapy-general (FACT-G) in women with hormone receptor positive metastatic breast cancer receiving letrozole plus lapatinib or letrozole alone. Value Health 2010;3:43 Abstract PCN0105.
104. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer 2006;95:683-90.
105. Oxford Outcomes. Utility measurement study for patients with metastatic breast cancer treated with Tyverb. Draft Report. 7 October 2009.
106. Doyle S, Lloyd A, Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer 2009;62:374-80.
107. Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. Health Technol Assess 2009;13(Suppl. 1):1-6.
108. Curtis L. Unit costs of health and social care 2009. Personal Social Services Research Unit, University of Kent; 2010. URL: www.pssru.ac.uk/uc/uc2009contents.htm (accessed 25 August 2010).
109. Cooper N, Abrams K, Sutton A, Turner D, Lambert P. A bayesian approach to markov modelling in cost effectiveness analyses: application to taxane use in advanced brest cancer. J Roy Statistical Society 2003;166:389-405.
110. Regional Drugs and Therapeutics Centre. The use of bevacizumab in the manaagment of metastatic breast cancer. 2007. URL: www.nyrdtc.nhs.uk/docs/eva/Bevacizumab%20MBC%20RDTC%20FINAL.pdf (accessed 25 August 2010).
111. National Institute for Health and Clinical Excellence (NICE). Lapatinib for the treatment of previously treated women with advanced, metastatic or recurrent breast cancer (final scope). 2007. URL: http://guidance.nice.org.uk/nicemedia/live/11731/35243/35243.pdf (accessed 25 August 2010).
112. Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population survey. Health Econ 1996;5:141-54.
113. Swain L. OPCS-4.5 chemotherapy regimens list & guidance for clinical coders version 2.0 dated 10th March 2010. 2010. URL: www.wales.nhs.uk/sites3/Documents/920/chemoreglistandguideopcs45v2.pdf/ (accessed 25 August 2010).
114. GlaxoSmithKline. A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer. URL: http://clinicaltrials.gov/ct2/show/NCT01160211 (accessed 24 November 2010).